HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)

Trodelvy (sacituzumab govitecan-hziy) • Neupogen (filgrastim)

22h

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy (clinicaltrials.gov)

P2, N=87, Not yet recruiting, National Cancer Institute (NCI)

22 hours ago

New P2 trial • Platinum sensitive

BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency)

BRCA2 mutation • BRCA1 mutation • HRD

Avastin (bevacizumab) • carboplatin • gemcitabine • pegylated liposomal doxorubicin • Trodelvy (sacituzumab govitecan-hziy) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)

Cost-Effectiveness Analysis of Sacituzumab Govitecan Versus Chemotherapy for the Treatment of Metastatic Triple-Negative Breast Cancer With Different Trophoblast Cell-Surface Antigen 2 Expression Levels in Chinese Mainland. (PubMed, Value Health Reg Issues)

In conclusion, although SG is clinically effective for mTNBC, its high cost makes it economically unfeasible in mainland China. A substantial price reduction is essential for it to become a viable option, enabling more patients to benefit from its therapeutic potential.

1 day ago

Journal • HEOR • Cost-effectiveness

TACSTD2 (Tumor Associated Calcium Signal Transducer 2)

Trodelvy (sacituzumab govitecan-hziy)

Effectiveness, safety, and biomarker analysis of sacituzumab govitecan in Chinese metastatic breast cancer: a multicenter real-world study. (PubMed, Ther Adv Med Oncol)

In conclusion, SG showed similar effectiveness with ASCENT and TROPiCS-02 study in heavily pretreated Chinese MBC patients. Given the compromised effectiveness in patients with prior PD-1/PD-L1 inhibitors or PIK3CA mutation, future investigations are warranted to explore SG-based combination regimens or novel therapeutic strategies in the above population.

1 day ago

Journal • Real-world evidence • PD(L)-1 Biomarker • IO biomarker

HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)

HR positive • HER-2 negative • PIK3CA mutation

Trodelvy (sacituzumab govitecan-hziy)

Sacituzumab Govitecan in Recurrent Glioblastoma (clinicaltrials.gov)

P2, N=32, Recruiting, The University of Texas Health Science Center at San Antonio | Trial completion date: Aug 2026 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2027

2 days ago

Trial completion date • Trial primary completion date

MGMT (6-O-methylguanine-DNA methyltransferase) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)

IDH wild-type

Trodelvy (sacituzumab govitecan-hziy)

SURE-01: Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer (clinicaltrials.gov)

P2, N=44, Completed, IRCCS San Raffaele | Trial completion date: Jun 2025 --> Sep 2025 | Trial primary completion date: Jun 2025 --> Sep 2025 | Recruiting --> Completed

5 days ago

Trial completion • Trial completion date • Trial primary completion date

cisplatin • irinotecan • Trodelvy (sacituzumab govitecan-hziy)

Sacituzumab govitecan in Japanese participants with HR+/HER2- metastatic breast cancer: primary results from the phase II ASCENT-J02 study. (PubMed, Jpn J Clin Oncol)

Although the primary endpoint (ORR by IRC) was not met (P > .025), overall efficacy results were generally similar to TROPiCS-02, supporting access to SG in Japanese patients with HR+/HER2- mBC. Safety was consistent with the known and manageable SG safety profile.

6 days ago

P2 data • Journal

HER-2 (Human epidermal growth factor receptor 2)

HR positive • HER-2 negative • EGFR positive

Trodelvy (sacituzumab govitecan-hziy)

Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)

P2, N=30, Not yet recruiting, West China Hospital

8 days ago

New P2 trial • IO biomarker

Trodelvy (sacituzumab govitecan-hziy) • Cotelet (tagitanlimab)

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors (clinicaltrials.gov)

P1/2, N=120, Recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2027 --> Mar 2029 | Trial primary completion date: Mar 2026 --> Mar 2028

9 days ago

Trial completion date • Trial primary completion date

BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • CDK12 (Cyclin dependent kinase 12) • BRCA (Breast cancer early onset) • CHEK2 (Checkpoint kinase 2) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • CHEK1 (Checkpoint kinase 1) • BARD1 (BRCA1 Associated RING Domain 1) • RAD54L (DNA Repair And Recombination Protein RAD54) • FANCL (FA Complementation Group L) • PPP2R2A (Protein Phosphatase 2, Regulatory Subunit B, Alpha)

BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation

berzosertib (M6620) • Trodelvy (sacituzumab govitecan-hziy)

15d

DF1001-001: Study of DF1001 in Patients With Advanced Solid Tumors (clinicaltrials.gov)

P1/2, N=270, Completed, Dragonfly Therapeutics | Recruiting --> Completed | Trial completion date: Dec 2026 --> Dec 2025 | Trial primary completion date: Oct 2026 --> Dec 2025

15 days ago

Trial completion • Trial completion date • Trial primary completion date • First-in-human

HER-2 (Human epidermal growth factor receptor 2)

HER-2 positive • HER-2 overexpression • HER-2 negative • HER-2 mutation • HER-2 positive + HER-2 overexpression

HercepTest

Opdivo (nivolumab) • albumin-bound paclitaxel • Trodelvy (sacituzumab govitecan-hziy) • DF1001

16d

VELOCITY-Lung: Study of Novel Treatment Combinations in Patients With Lung Cancer (clinicaltrials.gov)

P2, N=270, Recruiting, Gilead Sciences | N=593 --> 270

16 days ago

Enrollment change

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)

Opdivo (nivolumab) • cisplatin • carboplatin • docetaxel • albumin-bound paclitaxel • pemetrexed • Yutuo (zimberelimab) • Trodelvy (sacituzumab govitecan-hziy) • domvanalimab (AB154) • etrumadenant (AB928)

17d

Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer. (clinicaltrials.gov)

P1/2, N=75, Active, not recruiting, Massachusetts General Hospital | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2025 --> Jun 2026

17 days ago

Enrollment closed • Trial primary completion date

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)

HER-2 positive • HER-2 negative • ER negative

Talzenna (talazoparib) • Trodelvy (sacituzumab govitecan-hziy)